Structures by: Gallo G.
Total: 18
C54H42Cu2N2O8
C54H42Cu2N2O8
IUCrJ (2020) 7, 1 83-89
a=24.633(11)Å b=12.093(4)Å c=15.509(6)Å
α=90° β=108.480(12)° γ=90°
C54H40Cu2F2N2O8
C54H40Cu2F2N2O8
IUCrJ (2020) 7, 1 83-89
a=24.9699(8)Å b=12.1074(4)Å c=15.4675(4)Å
α=90° β=108.8090(10)° γ=90°
C54H40Cu2F2N2O8
C54H40Cu2F2N2O8
IUCrJ (2020) 7, 1 83-89
a=10.3725(5)Å b=11.0398(5)Å c=12.0294(5)Å
α=71.3540(10)° β=66.2290(10)° γ=65.3560(10)°
C54H40Cu2F2N2O8
C54H40Cu2F2N2O8
IUCrJ (2020) 7, 1 83-89
a=25.1802(18)Å b=12.0004(9)Å c=15.5976(10)Å
α=90° β=108.802(2)° γ=90°
Poly[(μ~4~-phenylphosphonato)zinc(II)]
C6H5O3PZn
IUCrData (2019) 4, 9 x191222
a=14.8549(8)Å b=5.1581(3)Å c=10.5471(6)Å
α=90° β=105.816(2)° γ=90°
2(C26H31NO6),CH4O
2(C26H31NO6),CH4O
Journal of medicinal chemistry (2010) 53, 23 8387-8399
a=5.1805(1)Å b=17.2642(4)Å c=28.1040(6)Å
α=90° β=92.234(1)° γ=90°
C16H22N4NiO2S2
C16H22N4NiO2S2
CrystEngComm (2020)
a=9.1142(5)Å b=14.0364(6)Å c=7.8828(4)Å
α=90° β=100.883(4)° γ=90°
C17H20Cl2N4NiS2
C17H20Cl2N4NiS2
CrystEngComm (2020)
a=16.8134(6)Å b=14.9609(3)Å c=9.801Å
α=90° β=114.894(2)° γ=90°
C16H18N4NiS2
C16H18N4NiS2
CrystEngComm (2020)
a=9.3096(19)Å b=10.516(2)Å c=11.057(2)Å
α=68.06(3)° β=66.94(3)° γ=69.49(3)°
C16H18N4NiS2
C16H18N4NiS2
CrystEngComm (2020)
a=10.1030(6)Å b=11.2150(6)Å c=18.5450(9)Å
α=106.440(4)° β=94.390(4)° γ=111.050(4)°
C14H18FeN4O2S2
C14H18FeN4O2S2
CrystEngComm (2020) 22, 2 184-194
a=10.2833(6)Å b=12.3146(6)Å c=7.6860(3)Å
α=90° β=103.823(4)° γ=90°
C14H14CdN4S2
C14H14CdN4S2
CrystEngComm (2020) 22, 2 184-194
a=5.83966(12)Å b=17.8924(4)Å c=8.63648(18)Å
α=90° β=108.7512(15)° γ=90°
C8H7CdN3S2
C8H7CdN3S2
CrystEngComm (2020) 22, 2 184-194
a=5.8783(5)Å b=10.3023(10)Å c=10.5662(10)Å
α=71.108(11)° β=78.415(11)° γ=74.975(11)°
C8H7FeN3S2
C8H7FeN3S2
CrystEngComm (2020) 22, 2 184-194
a=5.6544(4)Å b=10.3052(8)Å c=10.4498(7)Å
α=70.083(5)° β=78.969(7)° γ=75.518(4)°
C14H14FeN4S2
C14H14FeN4S2
CrystEngComm (2020) 22, 2 184-194
a=11.2219(19)Å b=17.954(2)Å c=9.0559(14)Å
α=90° β=112.725(7)° γ=90°
C26H28FeN6S2
C26H28FeN6S2
CrystEngComm (2020) 22, 2 184-194
a=27.693(3)Å b=27.693(3)Å c=11.1885(10)Å
α=90° β=90° γ=120°
FeC14H14N4S2
FeC14H14N4S2
CrystEngComm (2020) 22, 2 184-194
a=20.2576(8)Å b=9.3191(3)Å c=19.2831(6)Å
α=90° β=116.135(2)° γ=90°
Trihydrate 1/1 salt between ((R)-3-Hydroxy-4-trimethylammonio)butiramide and ((1R,3S)-1,2,2-Trimethyl-1,3-cyclopentane dicarboxylic acid)
C17H38N2O9
Acta Crystallographica Section C (1997) 53, 11 1679-1682
a=6.610(2)Å b=11.3710(10)Å c=14.6830(10)Å
α=90° β=91.730(10)° γ=90°